Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.

GlobeNewsWire • Oct 27, 2026

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

GlobeNewsWire • Oct 19, 2026

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.

MarketBeat • Oct 1, 2026

Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.

GlobeNewsWire • Sep 23, 2026

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 11, 2026

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

GlobeNewsWire • Sep 3, 2026

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Zacks Investment Research • Aug 19, 2026

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Zacks Investment Research • Aug 19, 2026

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

Zacks Investment Research • Aug 13, 2026

Altimmune Q2 Earnings Call Highlights

Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.

MarketBeat • Aug 12, 2026